Drug to Drug Interaction Study With Ipragliflozin and Furosemide
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 24
- Registration Number
- NCT01611415
Absolute Bioavailability Study With Ipragliflozin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT01611428
A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 44
- Registration Number
- NCT01611363
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 260
- Registration Number
- NCT01604928
- Locations
- 🇧🇪
Site: 12, Brussels, Belgium
🇧🇪Site: 13, Edegem, Belgium
🇧🇪Site: 11, Gent, Belgium
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 32
- Registration Number
- NCT01579461
- Locations
- 🇸🇰
FNsP Bratislava, nemocnica akad. L. Dérera; Klinika pracovného lekárstva a toxikológie, Bratislava, Slovakia
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 189
- Registration Number
- NCT01565707
- Locations
- 🇺🇦
Site: 3853, Dnipropetrovsk, Ukraine
🇺🇦Site: 3854, Kharkiv, Ukraine
🇩🇰Site: 4502, Kolding, Denmark
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 76
- Registration Number
- NCT01565694
- Locations
- 🇩🇰
Site DK4501, Aarhus, Denmark
🇭🇺Site HU3602, Miskolc, Hungary
🇲🇽Site MX5203, Leon, Mexico
To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis
Terminated
- Conditions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1
- Registration Number
- NCT01533844
- Locations
- 🇩🇪
Site: 4904, Hanover, Germany
🇫🇷Site: 3301, Poissy, Paris, France
🇩🇪Site: 4902, Erlangen, Germany
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1307
- Registration Number
- NCT01340027
- Locations
- 🇫🇷
FR33111, Paris Cedex 13, France
🇸🇰SK42109, Banska Bystrica, Slovakia
🇸🇰SK42106, Piestany, Slovakia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
- First Posted Date
- 2009-11-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1067
- Registration Number
- NCT01021332
© Copyright 2024. All Rights Reserved by MedPath